Blockade of IL-3 is a promising novel strategy for RA therapy

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory

disorder that attacks the joints producing an inflammatory synovitis. About 1% of the world‘s population is afflicted by rheumatoid arthritis, which is associated with high costs and, if not treated appropriately, with a reduction in life expectancy. Current treatment options include small molecules like methotrexate or biologics like TNFa-blockers, but about 20 % of patients show little or no response to currently available therapies or suffer from severe long term side effects like infections (i.e. tuberculosis, viral brain infections) or cancer (i.e. lymphomas). Clearly, an effective RA drug has blockbuster potential as shown by TNFa-blocker Humira® (Abbott Laboratories) with annual worldwide sales of 4.5 Billion USD in 2008 (data by Medtrack).

Further Information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

The Sound of the Perfect Coating

Fraunhofer IWS Transfers Laser-based Sound Analysis of Surfaces into Industrial Practice with “LAwave”. Sound waves can reveal surface properties. Parameters such as surface or coating quality of components can be…

Customized silicon chips

…from Saxony for material characterization of printed electronics. How efficient are new materials? Does changing the properties lead to better conductivity? The Fraunhofer Institute for Photonic Microsystems IPMS develops and…

Acetylation: a Time-Keeper of glucocorticoid Sensitivity

Understanding the regulatory mechanism paves the way to enhance the effectiveness of anti-inflammatory therapies and to develop strategies to counteract the negative effects of stress- and age-related cortisol excess. The…

Partners & Sponsors